NCT03472950View on ClinicalTrials.gov

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 11, 2018

Primary Completion Date

December 11, 2020

Study Completion Date

December 9, 2022

Conditions
ALS
Interventions
DRUG

Ranolazine 500 MG

Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).

DRUG

Ranolazine 1000 MG

Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

University of Kansas Medical Center

OTHER